Sign Out
Pulmonary arterial hypertension: Treatment of pulmonary artery hypertension (PAH) (WHO Group I) in patients with WHO/NYHA Class II, III, or IV symptoms to improve exercise capacity and decrease the rate of clinical deterioration.
Note: According to treatment guidelines from the Fifth World Symposium on Pulmonary Hypertension (WSPH), only a small number of PAH patients with WHO-FC IV symptoms (ie, severely ill patients) were included in clinical trials, therefore, most experts consider bosentan second-line therapy in these patients.
Continue with Google